Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Training Network for the Development of Bacterial ExoPolysaccharides for the treatment of Inflammatory Conditions

Objective

The essence of this proposal is to establish a collaborative training network which will develop novel immune-regulatory molecules from Bifidobacterium infantis 35624, for treatment of inflammatory diseases. A multidisciplinary team of four prestigious European partners has been assembled (SME & Coordinator - Alimentary Health Ltd (expert in developing probiotic products); Swiss Institute for Asthma and Allergy Research, (expert in immune-regulation); Vienna Institute of Biotechnology at Universität für Bodenkultur (expert in glycobiology); and University College Cork, Alimentary Pharmabiotics Centre and Department of Microbiology (expert in bioinformatics and glycobiology assembly in probiotic bacteria). Each partner will provide unique critical expertise, through knowledge, personnel and facilities which will be complementary and additive and will provide the synergistic expertise required to successfully deliver on the goal of this project and forge a long-lasting relationship. The end result: a unique opportunity for cross-sector state-of-the-art knowledge transfer and dissemination, through the identification of molecules from B. infantis 35624 with proven efficacy in the treatment of IBS and other inflammatory conditions – expected to have major commercialization, economic and health implications.
B. infantis 35624 is a commensal micro-organism, originally isolated from human gastrointestinal tissue, which has demonstrated unique properties in human clinical studies. B. infantis 35624 consumption is associated with significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in two appropriately designed studies. No other bacterial strain has shown significant improvement in Irritable Bowel Syndrome (IBS) symptoms. The exact mechanisms underpinning the clinical benefit are not known but modulation of the host immune response is strongly believed to play a role.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-PEOPLE-2011-IAPP
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinator

SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
EU contribution
€ 270 026,00
Address
OBERE STRASSE 22
7270 Davos Platz
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Ostschweiz Graubünden / Grigioni / Grischun
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (4)

My booklet 0 0